Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU

Li,Zhiying; Xia,Yun; Bu,Xingyao; Yang,Dongyi; Yuan,Yiqiang; Guo,Xiaohe; Zhang,Gangzhong; Wang,Zhanwei; Jiao,Jichao

doi:10.3892/ol.2018.8551

Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU

Authors:
- Zhiying Li
- Yun Xia
- Xingyao Bu
- Dongyi Yang
- Yiqiang Yuan
- Xiaohe Guo
- Gangzhong Zhang
- Zhanwei Wang
- Jichao Jiao
View Affiliations

Affiliations: Department of Neurosurgery, Zhengzhou No. 7 People's Hospital, Zhengzhou, Henan 450000, P.R. China, Department of Microbiology and Immunology, Zhengzhou Health School, Zhengzhou, Henan 450000, P.R. China, Department of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: April 20, 2018 https://doi.org/10.3892/ol.2018.8551
Pages: 9877-9883
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effect of valproic acid (VPA) on the susceptibility of glioma stem cells to temozolomide (TMZ) and nimustine (ACNU), the O6‑methylguanine‑DNA methyltransferase (MGMT) promoter methylation and its expression of MGMT were examined. A total of 3 glioma cell populations were isolated from human glioma tissues, and immunocytochemistry was used to detect the expression of MGMT. VPA inhibition on the growth of the 3 glioma cell populations exposed to various concentrations of TMZ and ACNU was evaluated. Flow cytometry was applied to detect the apoptosis of glioma cells, and a methylation‑specific polymerase chain reaction was used to identify methylation of MGMT promoter. Immunocytochemistry results indicated that MGMT was negatively expressed in the G1 population, but positively expressed in the G2 and G3 populations. Cell growth inhibition assays demonstrated that the survival rate in the VPA + TMZ or ACNU groups was decreased compared with that of the TMZ or ACNU alone groups (P<0.05). As for the apoptotic rate, those in the VPA alone group were increased compared with the control group (P<0.05), and the rates in the VPA + TMZ or ACNU groups were increased compared with TMZ or ACNU alone groups (P<0.05). The expression of MGMT remained negative in the G1 population following treatment with VPA, but MGMT expression became negative in the 2 MGMT‑positive cell populations (G2 and G3) following VPA treatment. The MGMT promoter in the G1 population was partially methylated in the control group, but was fully methylated following VPA treatment, while the promoters of G2, G3 were unmethylated in the control group and became partially methylated in the VPA treatment group. Taken together, TMZ and ACNU may suppress the growth of glioma stem cells in vitro in a dose‑dependent manner. VPA may enhance the inhibitory effects of various concentrations of TMZ and ACNU on the growth of MGMT‑negative/positive cells, particularly on MGMT‑positive cell populations. VPA itself may induce the apoptosis of glioma cells, and VPA combined with TMZ or ACNU may enhance TMZ/ACNU‑induced apoptosis of glioma stem cells. Furthermore, VPA may also promote the methylation of the MGMT promoter to silence MGMT expression in glioma cells, which may be an important mechanism through which VPA enhances the efficacy of TMZ and ACNU in targeting glioma stem cells.

View Figures

View References

1	Lu B, Zhou Y, Su Z, Yan A and Ding P: Effect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line. Mol Med Rep. 16:3387–3394. 2017. View Article : Google Scholar : PubMed/NCBI
2	Dong J, Zhao Y, Huang Q, Fei X, Diao Y, Shen Y, Xiao H, Zhang T, Lan Q and Gu X: Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev. 7:141–152. 2011. View Article : Google Scholar : PubMed/NCBI
3	Audia A, Conroy S, Glass R and Bhat KPL: The impact of the tumor microenvironment on the properties of glioma stem-like cells. Front Oncol. 7:1432017. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
5	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versusradiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wakabayashi T, Yoshida J, Mizuno M and Kajita Y: Intratumoral microinfusion of nimustine (ACNU) for recurrent glioma. Brain Tumor Pathol. 18:23–28. 2001. View Article : Google Scholar : PubMed/NCBI
7	Kaina B, Ziouta A, Ochs K and Coquerelle T: Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: Facts and models. Mutat Res. 381:227–241. 1997. View Article : Google Scholar : PubMed/NCBI
8	D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 54:334–341. 1998. View Article : Google Scholar : PubMed/NCBI
9	Brennand J and Margison GP: Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cell sharboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci USA. 83:6292–6296. 1986. View Article : Google Scholar : PubMed/NCBI
10	Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 4:296–307. 2004. View Article : Google Scholar : PubMed/NCBI
11	Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N and Stupp R: Clinical trial substantiates the predictive value of O-6-methylguanine-DNAmethyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
12	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
13	Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kostrouchová M, Kostrouch Z and Kostrouchová M: Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha). 53:37–49. 2007.PubMed/NCBI
15	Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H and Cinatl J Jr: Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 65:520–527. 2004. View Article : Google Scholar : PubMed/NCBI
16	Riva G, Butta V, Cilibrasi C, Baronchelli S, Redaelli S, Dalprà L, Lavitrano M and Bentivegna A: Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity. Oncol Rep. 35:2811–2824. 2016. View Article : Google Scholar : PubMed/NCBI
17	Xu H, Song XD, Li Y and Dai J: The new method of cells growing on the glass slide. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 25:283–285. 2009.(In Chinese). PubMed/NCBI
18	Ku JL, Jeon YK and Park JG: Methylation-specific PCR. Methods Mol Biol. 791:23–32. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chen H, Zhang JH, Li BY, Zhang XQ, Gao HQ, Xu XQ and Wang JFL: The application of hematoxylin stain method in determining the effect of non-monomer herbal extract on the cell proliferation. Chin J Biochem Pharm. 31:183–185. 2010.(In Chinese).
20	Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaña C, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
21	Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793–797. 1999.PubMed/NCBI
22	Kim JH, Shin JH and Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys. 59:1174–1180. 2004. View Article : Google Scholar : PubMed/NCBI
23	Alvarez AA, Field M, Bushnev S, Longo MS and Sugaya K: The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells. J Mol Neurosci. 55:7–20. 2015. View Article : Google Scholar : PubMed/NCBI
24	Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, Saito K and Wakabayashi T: Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol. 92:15–22. 2009. View Article : Google Scholar : PubMed/NCBI
25	Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M and Chen H: Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 12:942–951. 2007. View Article : Google Scholar : PubMed/NCBI
26	Rodriguez-Menendez V, Gilardini A, Bossi M, Canta A, Oggioni N, Carozzi V, Tremolizzo L and Cavaletti G: Valproate protective effects on cisplatin-induced peripheral neuropathy: An in vitro and in vivo study. Anticancer Res. 28:335–342. 2008.PubMed/NCBI
27	Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P and Stalpers LJ: Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol. 107:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, Jeong CH, Hou Y and Jeun SS: Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol. 2012:9874952012. View Article : Google Scholar : PubMed/NCBI